NCT03802344 - This Trial is a Randomised, Multicentre, Investigator-blind, Vehicle and Comparator-controlled, Parallel-group Trial With the Purpose of Evaluation Efficacy, Safety and Convenience of the MC2-01 Cream | Biotech Hunter

Enrollment

498

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

October 2, 2019

Study Completion Date

October 2, 2019

Conditions

Psoriasis Vulgaris

Interventions

DRUG

MC2-01 cream

MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream

DRUG

Cal/BDP combination

Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%

DRUG

Vehicle

Vehicle cream

Trial Locations (2)

University Medical Center Hamburg, Hamburg

Dermatovenerologie a korektivní dermatologie, Prague